HOME >> BIOLOGY >> NEWS
UT Southwestern scientists explain how the injured brain remodels itself

DALLAS Nov. 1, 2001 - Researchers at UT Southwestern Medical Center at Dallas have begun to reveal the cellular mechanisms critical for restoring brain functions after traumatic injuries a step that could lead to effective treatments of paralysis and other brain and spinal-cord damage.

The study indicated that the injured brains long-observed restorative powers at least partially derive from generating waves of adult-neural stem cells, or specialized precursors, to develop into critically needed replacement neurons and astrocytes. Neurons, the basic building blocks of the nervous system, and astrocytic cells, which provide metabolic functions between neurons and blood vessels, are crucial to restoring or remodeling damaged brain and spinal-cord tissue.

Published in the Nov. 1 issue of the Journal of Neuroscience Research, the study involving adult mice showed that following traumatic brain injury, the brains stem-cell proliferation continues at a rapid pace and persists over a much longer time than expected, both at the injury site and even in the most-distant areas affected by the injury, said Dr. Steven G. Kernie, assistant professor of pediatrics and lead researcher.

The findings suggest that manipulating the expression of stem-cell regulators might accelerate or prolong the regeneration of neurons in humans, said Kernie, who collaborated with Dr. Luis F. Parada, director of the Center for Developmental Biology and the Kent Waldrep Foundation Center for Basic Research on Nerve Growth and Regeneration.

We wanted to answer some basic questions about the persistence of neural stem cells proliferating into adulthood, Kernie said. Our study of traumatic brain injuries in adult mice found that natures own restorative powers are more extensive than previously thought. Perhaps even more exciting, we found that the regenerative powers are widespread, not just in the immediate area of the injury. Though using mice, our study raises the pos
'"/>

Contact: Worth Wren Jr.
Worth.Wren@UTSouthwestern.edu
214-648-3404
UT Southwestern Medical Center
1-Nov-2001


Page: 1 2

Related biology news :

1. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative
2. UT Southwestern biochemist honored with NIH Directors Pioneer Award
3. RSV can increase the risk of asthma, UT Southwestern researchers find
4. Searle Scholars program awards $240,000 to UT Southwestern researcher
5. Two molecules work together to aid transport of immune cells, UT Southwestern researchers find
6. Biochemist becomes 15th UT Southwestern faculty member serving on National Academy of Sciences
7. UT Southwestern researchers reveal mechanisms of smooth-muscle contraction
8. Fetal lungs provide a signal initiating labor, UT Southwestern researchers find
9. UT Southwestern researchers cite recent advances in underlying causes of rare body-fat disorders
10. UT Southwestern researchers discover link that could aid in treatment of kidney cyst diseases
11. UT Southwestern research halts narcolepsy symptoms

Post Your Comments:
(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
(Date:5/11/2015)... Ohio , May 11, 2015  Through a well-rounded ... Ohio had a strong showing at AUVSI,s Unmanned ... These representatives of Ohio,s UAS industry ... and abroad from all points along the UAS ecosystem. ... Development Coalition,s (DDC) Vice President for Aerospace Rich Knoll ...
(Date:5/10/2015)... GOTHENBURG, Sweden , May 11, 2015 ... touch fingerprint sensors FPC1025 and FPC1155 from the distributor World ... one of FPC,s distributors in Asia . ... the sensors will be used by smartphone manufacturers in ... is included in the communicated revenue guidance of + 1 000 ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
(Date:5/21/2015)... Specialty Pharmacy Times has completed its ... BPA Worldwide as a business publication member. As ... for Specialty Pharmacy Times based on business/distribution, demographics ... member of BPA Worldwide, Specialty Pharmacy Times shows ... the most reliable, unequaled data,” said Chris Hennessy, ...
(Date:5/21/2015)... 21, 2015  The EveryLife Foundation for Rare ... and Amy Klobuchar (D-MN) today for ... & Treatments, or OPEN ACT. Supported ... organizations, this bipartisan legislation promises to rapidly bring ... rare disease patients by incentivizing drug makers to ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
(Date:5/21/2015)... Veolia’s environmental monitoring technology division, ... distribution agreement with VWR to distribute TECTA™ B16, ... than 160 years of experience, VWR, a leading ... and production facilities, has cultivated a value proposition ... to enable science. Endetec’s TECTA™ B16, combines ...
Breaking Biology Technology:Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Veolia’s TECTA™ B16 Instrument for E. Coli Detection is Offered Exclusively Through VWR 2
Cached News: